The last day of trading with the warrants of series TO2 in Pharmacolog i Uppsala AB is today, October 13, 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW.

Today, October 13, 2023, is the last day of trading with the warrants of series TO2 in Pharmacolog i Uppsala AB (“Pharmacolog” or “the Company”). The subscription period for the warrants of series TO2 runs up until October 18, 2023. Each warrant of series TO2 gives the owner the right to subscribe for one point zero eight (1.08) new shares in the Company at a subscription price of SEK 0.18 per share.

If all the warrants of series TO2 are exercised, the Company will receive approximately SEK 0.37 million before issue costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than October 18, 2023, or sell the warrants no later than October 13, 2023. Please observe that certain nominees might close their application earlier than October 18, 2023.

Summarized terms for the warrants of series TO2:

Exercise period: October 4, 2023 - October 18, 2023.

Issue volume: 2,049,966 warrants of series TO2 entitle the holder to subscribe for 2,213,963 shares of series B. Upon full utilization, the Company will receive approximately SEK 0.37 million before issue costs.

Subscription price: 0.18 SEK per share.

Last day for trading with warrants of series TO2: October 13, 2023.

Share capital and dilution: Upon full exercise of the warrants, the share capital will increase by SEK 391,871.45, from SEK 11,719,858.53 to SEK 12,111,729.98. The number of shares increases upon full exercise by 2,213,963 shares, from 66,213,890 shares to 68,427,853 shares. The dilution at full utilization amounts to approximately 3.24 percent of the existing number of shares and votes in the Company.

Please note that the warrants that are not exercised no later than October 18, 2023, or disposed of no later than October 13, 2023, will expire worthless. In order for the warrants not to expire, active subscription of shares or disposal of the warrants is required.

How the warrants are used to subscribe for new shares in the Company:

Nominee-registered warrants (Custody account)

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

Direct-registered warrants (Securities account)

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Advisor

Mangold Fondkommission AB is financial advisor to Pharmacolog in connection with the utilization of warrants. Eversheds Sutherland Advokatbyrå AB is legal advisor to the Company in connection with the utilization of warrants.